For patients with acute myeloid leukemia (AML) receiving intensive chemotherapy, AML-SCORE and PINA-Score help to estimate 1) complete remission and early death rate in patients ≥60 years and 2) probabilities of overall and relapse-free survival in patients with AML with normal karyotype.
SAL Study Alliance Leukemia
AMLCG

Contact

Wolfgang E Berdel, MD
University of Muenster, Department of Medicine A
Phone: +49-(0)251/83-47587
Fax: +49-(0)251/83-47588

Carsten Müller-Tidow, MD
University of Halle, Department of Medicine IV
Phone: +49-(0)345/557-2924
Fax: +49-(0)345/557-2950

Utz Krug, MD
Leverkusen Hospital, Department of Medicine 3
Phone: +49-(0)214/13-2671
Fax: +49-(0)214/13-2198

If you want to contact our team, please email us: info[at]aml-score.org

 

AML-Score

Carsten Müller-Tidow, MD

Phone: +49-(0)251/83-56229

Fax: +49-(0)251/83-52673



Utz Krug, MD

Phone: +49-(0)251/83-46012

Fax: +49-(0)251/83-52673

If you want to contact our team, please email us: info[at]aml-score.org

 

PINA-Score

Friederike Pastore, MD

Eva Hoster, PhD

Karsten Spiekermann, MD

If you want to contact our team, please email us: PINA[at]aml-score.org